In breast cancer, clinical trials are being performed to investigate the potential of phenelzine sulfate, an LSD1 inhibitor, combined with nanoparticle albumin-bound paclitaxel, Abraxane, for metastatic or advanced tumor (NCT03505528). The gene discussed is KDM1A; the disease is breast cancer.